| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Department of Endocrinology, Diabetes, and Nutrition, Klinikum Benjamin Franklin, Freie Universität Berlin (S.D., E.E., P.B., M.Q., C.B.-V., M.R., W.O., V.B.), and Research Laboratories of Schering AG (D.S., P. E.), 12200 Berlin, Germany
Address all correspondence and requests for reprints to: Dr. Sven Diederich, Department of Endocrinology, Diabetes, and Nutrition, Klinikum Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. E-mail: diederich{at}ukbf.fu-berlin.de.
Abstract
The 11ß-hydroxysteroid dehydrogenase (11ß-HSD) system plays a pivotal role in glucocorticoid (GC) and mineralocorticoid (MC) action. Although 11ß-HSD activities are important determinants for the efficacy of synthetic MCs and GCs, corresponding pharmacokinetic data are scanty. Therefore, we characterized 11ß-HSD profiles for a wide range of steroids often used in clinical practice. 11ß-HSD1 and 11ß-HSD2 were selectively examined in 1) human liver and kidney cortex microsomes, and 2) Chinese hamster ovarian cells stably transfected with 11ß-HSD1 or 11ß-HSD2 expression vectors. Both systems produced concordant evidence for the following conclusions.
Oxidation of steroids by 11ß-HSD2 is diminished if they are fluorinated in position 6
or 9 (e.g. in dexamethasone) or methylated at 2 or 6 (in methylprednisolone) or 16 or 16ß, by a methylene group at 16 (in prednylidene), methyloxazoline at 16, 17 (in deflazacort), or a 2-chlor configuration. Whereas the methyl groups also decrease reductase activity (steric effects), fluorination increases reductase activity (negative inductive effect), leading to a shift to reductase activity. This may explain the strong MC activity of 9-fluorocortisol and should be considered in GC therapy directed to 11ß-HSD2-expressing tissues (kidney, colon, and placentofetal unit). 11ß-HSD2 oxidation of prednisolone is more effective than that of cortisol, explaining the reduced MC activity of prednisolone compared with cortisol.
Reduction by 11ß-HSD1 is diminished by 16-methyl, 16ß-methyl, 2-methyl, and 2-chlor substitution, whereas it is increased by the 
1-dehydro configuration in prednisone, resulting in higher hepatic first pass activation of prednisone compared with cortisone.
To characterize a GC or a MC as substrate for the different 11ßHSDs may be essential for an optimized steroid therapy.
This article has been cited by other articles:
 |
|
 |
|
  H. Filipsson and G. Johannsson GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies Eur. J. Endocrinol., November 1, 2009; 161(S1): S85 - S95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hofbauer and M. Rauner Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells Mol. Endocrinol., October 1, 2009; 23(10): 1525 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V J Heazlewood, M Ratnapala, and L Cochrane Successful use of dexamethasone when prednisolone is not tolerated Obstet Med, September 1, 2009; 2(3): 132 - 132. [Full Text] [PDF]
|
|
|
|
|
|
K. Lovas, C. G Gjesdal, M. Christensen, A. B Wolff, B. Almas, J. Svartberg, K. J Fougner, U. Syversen, J. Bollerslev, J. A Falch, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone Eur. J. Endocrinol., June 1, 2009; 160(6): 993 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kim, K. X. Kim, N. N. Raveendran, T. Wu, S. R. Pondugula, and D. C. Marcus Regulation of ENaC-mediated sodium transport by glucocorticoids in Reissner's membrane epithelium Am J Physiol Cell Physiol, March 1, 2009; 296(3): C544 - C557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, F. Park, J. L. Pietrusz, G. Jia, R. J. Singh, B. C. Netzel, and M. Liang Suppression of 11{beta}-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis Physiol Genomics, February 19, 2008; 32(3): 343 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Tomlinson, M. Sherlock, B. Hughes, S. V. Hughes, F. Kilvington, W. Bartlett, R. Courtney, P. Rejto, W. Carley, and P. M. Stewart Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jakobsson, J. A. Jorgensen, and A. Jacobsson Differential regulation of fatty acid elongation enzymes in brown adipocytes implies a unique role for Elovl3 during increased fatty acid oxidation Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E517 - E526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Leonard, C. Godson, H. R. Brady, and C. T. Taylor Potentiation of Glucocorticoid Activity in Hypoxia through Induction of the Glucocorticoid Receptor J. Immunol., February 15, 2005; 174(4): 2250 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gulati, K. Gulati, T. Sugiyama, H. Tanaka, T. Taguchi, M. S. Cooper, P. M. Stewart, M. B. Leonard, B. S. Zemel, and V. A. Stallings Glucocorticoids and Bone Mineral Content in the Childhood Nephrotic Syndrome N. Engl. J. Med., December 16, 2004; 351(25): 2655 - 2657. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Tomlinson, E. A. Walker, I. J. Bujalska, N. Draper, G. G. Lavery, M. S. Cooper, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response Endocr. Rev., October 1, 2004; 25(5): 831 - 866. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
